Developing iPSC-Derived Liver Systems for MASLD Modeling and Therapy Screening

In this GEN webinar, Prof. Jeremy Tomlinson will discuss the pathogenesis of MASLD, share examples from recent research that highlight current progress and advancements in the clinic, and explore the importance of developing efficient pre-clinical models to identify and characterize novel cellular targets associated with disease progression.

During the webinar, you will learn about DefiniGEN’s highly characterized iPSC-derived hepatocytes (Opti-HEP), and how these cells can recapitulate the disease phenotype in vitro, offering an optimal pre-clinical platform for the large-scale screening of novel therapeutics against MASLD.

Discover how iPSC derived cells can be used to support the development of drug and gene therapies

In this webinar you will discover how iPSC derived cells can be used to advance the efficiency and efficacy of disease modeling. The webinar will cover topics including functionality, modeling disease phenotypes, therapeutic modalities and delivery and efficacy.

White paper

In this white paper you will discover how human induced pluripotent stem cell derived hepatocyte-like cells (HLCs) have the potential to act as an ideal model for the study of liver diseases, combining the expansion capacity and phenotypic stability of hepatoma cell lines with the functionality and normal karyotype of primary hepatocytes.

Within the white paper you will also learn more about DefiniGEN’s iPSC-derived HLC platform which is capable of screening candidate therapeutics with high accuracy and reproducibility.